A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
Recruiting now Phase 2 NCT04641247
Run by GlaxoSmithKline · for 18 and older · All sexes
What this study is about
This is a global extension study to provide continued access to niraparib and further characterize the long-term safety of niraparib treatment in participants who are currently receiving treatment with niraparib within GlaxoSmithKline/TESARO-sponsored studies (NCT01847274, NCT02354586, NCT01905592, NCT03308942, NCT02657889) that has fulfilled the requirements for the primary objective.
Who can join (things the study team will check)
✅ You may be able to join if…
- Participant is able to understand the study procedures and agrees to participate in the study by providing written informed consent.
- Participant is willing and able to comply with scheduled visits, treatment plans, and any other study procedures.
- Participant is currently receiving treatment with niraparib (as monotherapy or in combination) in a GlaxoSmithKline/TESARO-sponsored study that has fulfilled the requirements for the primary objective.
- Participant is currently benefiting from treatment with niraparib as assessed by the Investigator according to the parent study protocol requirements.
- Participants of childbearing potential who are sexually active and their partners must agree to the use of an effective form of contraception throughout their participation during study treatment through 180 days after last dose of study drug.
🚫 You may not be able to join if…
- Participant has been permanently discontinued from niraparib treatment in the parent study for any reason.
- Participant currently has unresolved toxicities for which niraparib dosing has been interrupted in the parent study. Participants meeting all other eligibility criteria may be enrolled once toxicities have resolved to allow niraparib treatment to resume.
- Participant is pregnant or is expecting to conceive children while receiving study drug or for up to 180 days after the last dose of study drug. Participant is breastfeeding or is expecting to breastfeed within 30 days of receiving the final dose of study drug (women should not breastfeed or store breastmilk for use during niraparib treatment and for 30 days after receiving the final dose of study treatment).
Where this trial is running
- GSK Investigational Site, Tucson, Arizona, United States
- GSK Investigational Site, Encinitas, California, United States
- GSK Investigational Site, Los Angeles, California, United States
- GSK Investigational Site, Whittier, California, United States
- GSK Investigational Site, Jacksonville, Florida, United States
- GSK Investigational Site, Atlanta, Georgia, United States
- GSK Investigational Site, Harvey, Illinois, United States
- GSK Investigational Site, Boston, Massachusetts, United States
- GSK Investigational Site, Grand Rapids, Michigan, United States
- GSK Investigational Site, Morristown, New Jersey, United States
- GSK Investigational Site, Lake Success, New York, United States
- GSK Investigational Site, Charlotte, North Carolina, United States
+ 13 more sites.
Who to contact
US GSK Clinical Trials Call Center · 877-379-3718 · GSKClinicalSupportHD@gsk.com
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT04641247.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.
Beacon is an information tool, not medical advice. Whether a trial is right for you is a decision for you, your doctor, and the study team. Trial details come from the official registry, ClinicalTrials.gov, and may change — always confirm with the study team. Beacon collects no data about you: this page has no cookies, no accounts, and no tracking.